Mydecine Innovations Group Inc.
MYCO
CNSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -32.04% | -42.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.04% | 117.83% | |||
| Operating Income | 32.04% | -117.83% | |||
| Income Before Tax | 95.49% | -111.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 95.49% | -111.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 95.49% | -111.55% | |||
| EBIT | 32.04% | -117.83% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 94.12% | -111.60% | |||
| Normalized Basic EPS | 71.43% | -131.53% | |||
| EPS Diluted | 94.12% | -111.60% | |||
| Normalized Diluted EPS | 71.43% | -131.53% | |||
| Average Basic Shares Outstanding | 0.00% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||